Literature DB >> 15890575

A permanent breast seed implant as partial breast radiation therapy for early-stage patients: a comparison of palladium-103 and iodine-125 isotopes based on radiation safety considerations.

Brian Keller1, Raxa Sankreacha, Eileen Rakovitch, Peter O'brien, Jean-Philippe Pignol.   

Abstract

PURPOSE: A permanent breast seed implant (PBSI) technique has been developed as a new form of partial adjuvant radiation therapy for early-stage breast cancer. This study compares iodine-125 ((125)I) and palladium-103 ((103)Pd) isotopes by examining the exposure and effective dose (ED) to a patient's partner. METHODS AND MATERIALS: A low-energy survey meter was used to measure exposure rates as a function of bolus thickness placed over (103)Pd or (125)I seeds. A general mathematical expression for the initial exposure rate at 1 m (x(o,1m)) from the skin surface as a function of the implant size, R, and the distance between the skin surface and the implant, d, was derived. Also, a second general equation is proposed to calculate the ED to the patient's partner.
RESULTS: The initial exposure rate at 1 meter and the ED are calculated as follows: x(o,1m) = 3alpha2R(3) ; ;beta(3) [e(-beta(2R+d))(betaR + 1) + e(-betad)(betaR - 1)], and ED = aR(b) [e(-c(2R+d)) (cR + 1) + e(-cd) (cR - 1)]. For (125)I, the parameters are: alpha = 0.154409, beta = 0.388460, a = 197, b = -0.95, and c = 0.38846. For (103)Pd, they are: alpha = 0.06877, beta = 0.421098, a = 18.6, b = -0.78, and c = 0.421098. For implant diameters varying from 2 to 6 cm and skin-to-implant distances varying from 0.7 to 4 cm, the ED is consistently below 2.6 mSv using the (103)Pd isotope, but more than 5 mSv in many instances and possibly up to 20 mSv using (125)I.
CONCLUSIONS: PBSI using (103)Pd seeds appears safe because the patient's partner ED is consistently below 5 mSv. The(125)I isotope is not recommended for PBSI.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15890575     DOI: 10.1016/j.ijrobp.2004.10.014

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  7 in total

1.  Dosimetric intercomparison of permanent Ho-166 seed's implants and HDR Ir-192 brachytherapy in breast cancer.

Authors:  Tarcisio Passos Ribeiro de Campos; Luciana Batista Nogueira; Bruno Trindade; Ethel Mizrahy Cuperschmid
Journal:  Rep Pract Oncol Radiother       Date:  2016-01-04

2.  Radiation protection of persons living close to patients with radioactive implants.

Authors:  Theodor W Kaulich; Michael Bamberg
Journal:  Strahlenther Onkol       Date:  2010-01-28       Impact factor: 3.621

3.  Modelling a new approach for radio-ablation after resection of breast ductal carcinoma in-situ based on the BAT-90 medical device.

Authors:  Anna Sarnelli; Matteo Negrini; Emilio Mezzenga; Giacomo Feliciani; Marco D'Arienzo; Antonino Amato; Giovanni Paganelli
Journal:  Sci Rep       Date:  2022-01-07       Impact factor: 4.379

4.  Clinical application and accuracy assessment of imaging-based surgical navigation guided 125I interstitial brachytherapy in deep head and neck regions.

Authors:  Guohao Zhang; Zhiyuan Wu; Wenting Yu; Xiaoming Lyu; Wenjie Wu; Yi Fan; Yong Wang; Lei Zheng; Mingwei Huang; Yi Zhang; Chuanbin Guo; Jianguo Zhang
Journal:  J Radiat Res       Date:  2022-09-21       Impact factor: 2.438

5.  Brachytherapy in accelerated partial breast irradiation (APBI) - review of treatment methods.

Authors:  Janusz Skowronek; Magdalena Wawrzyniak-Hojczyk; Kinga Ambrochowicz
Journal:  J Contemp Brachytherapy       Date:  2012-09-29

6.  A digital model individual template and CT-guided 125I seed implants for malignant tumors of the head and neck.

Authors:  Ming-Wei Huang; Shu-Ming Liu; Lei Zheng; Yan Shi; Jie Zhang; Yan-Sheng Li; Guang-Yan Yu; Jian-Guo Zhang
Journal:  J Radiat Res       Date:  2012-08-01       Impact factor: 2.724

7.  Magnetic field dose effects on different radiation beam geometries for hypofractionated partial breast irradiation.

Authors:  Anthony Kim; Stephanie Lim-Reinders; Claire McCann; Syed Bilal Ahmad; Arjun Sahgal; Justin Lee; Brian M Keller
Journal:  J Appl Clin Med Phys       Date:  2017-09-13       Impact factor: 2.102

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.